
Rebecca C Coll

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5917460/publications.pdf Version: 2024-02-01



REBECCA C COLL

#	Article	IF	CITATIONS
1	A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 2015, 21, 248-255.	30.7	1,967
2	Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nature Immunology, 2010, 11, 897-904.	14.5	1,149
3	MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nature Chemical Biology, 2019, 15, 556-559.	8.0	561
4	Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. Journal of Experimental Medicine, 2018, 215, 827-840.	8.5	396
5	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 ⁺ T cells. Science, 2016, 352, aad1210.	12.6	395
6	The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood, 2016, 128, 2960-2975.	1.4	271
7	Monounsaturated Fatty Acid–Enriched High-Fat Diets Impede Adipose NLRP3 Inflammasome–Mediated IL-1β Secretion and Insulin Resistance Despite Obesity. Diabetes, 2015, 64, 2116-2128.	0.6	229
8	NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends in Pharmacological Sciences, 2022, 43, 653-668.	8.7	193
9	Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Current Opinion in Immunology, 2013, 25, 40-45.	5.5	187
10	The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1Î ² transcription and activate the NLRP3 inflammasome. Journal of Biological Chemistry, 2017, 292, 12077-12087.	3.4	122
11	New Insights into the Regulation of Signalling by Toll-Like Receptors and Nod-Like Receptors. Journal of Innate Immunity, 2010, 2, 406-421.	3.8	121
12	NLRP3 inflammasome priming: A riddle wrapped in a mystery inside an enigma. Journal of Leukocyte Biology, 2020, 108, 937-952.	3.3	118
13	The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes. PLoS ONE, 2011, 6, e29539.	2.5	117
14	Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy, 2014, 16, 419.	3.5	86
15	Glutathione transferase Omega 1 is required for the lipopolysaccharide-stimulated induction of NADPH oxidase 1 and the production of reactive oxygen species in macrophages. Free Radical Biology and Medicine, 2014, 73, 318-327.	2.9	62
16	GSTO1-1 modulates metabolism in macrophages activated through the LPS and TLR4 pathway. Journal of Cell Science, 2015, 128, 1982-1990.	2.0	55
17	Questions and controversies in innate immune research: what is the physiological role of NLRP3?. Cell Death Discovery, 2016, 2, 16019.	4.7	48
18	Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals. Cellular and Molecular Immunology, 2017, 14, 118-126.	10.5	42

REBECCA C COLL

#	Article	IF	CITATIONS
19	Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors. ChemMedChem, 2017, 12, 1449-1457.	3.2	42
20	Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6480-E6489.	7.1	33
21	Evidence against a role for NLRP3-driven islet inflammation in db/db mice. Molecular Metabolism, 2018, 10, 66-73.	6.5	32
22	Mitochondrial DNA synthesis fuels NLRP3 inflammasome. Cell Research, 2018, 28, 1046-1047.	12.0	20
23	PHOrming the inflammasome: phosphorylation is a critical switch in inflammasome signalling. Biochemical Society Transactions, 2021, 49, 2495-2507.	3.4	8
24	Design, synthesis and evaluation of an NLRP3 inhibitor diazirine photoaffinity probe. Tetrahedron Letters, 2020, 61, 151849.	1.4	7
25	Role reversal: adaptive immunity instructs inflammasome activation for antiâ€viral defence. EMBO Journal, 2019, 38, e103533.	7.8	5
26	Caging NLRP3 tames inflammasome activity. Cell, 2021, 184, 6224-6226.	28.9	5
27	Activation of the Non-canonical Inflammasome in Mouse and Human Cells. Methods in Molecular Biology, 2022, 2459, 51-63.	0.9	3
28	NLRC3 Restrains Responses to a T. Immunity, 2018, 49, 989-991.	14.3	1
29	102. Cytokine, 2013, 63, 267.	3.2	0
30	Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia. Journal of Neuroimmunology, 2014, 275, 147.	2.3	0
31	A6.18â€Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, A62.2-A63.	0.9	0
32	1020 - NEW INSIGHTS INTO INFLAMMASOME SIGNALLING AND FUNCTION DURING INFLAMMATION. Experimental Hematology, 2019, 76, S32.	0.4	0